Glutamate, glutamate receptors, and downstream signaling pathways

International Journal of Biological Sciences

Volumn 9, Issue 9, 2013, Pages 948-959

  Willard, Stacey S ^a   Koochekpour, Shahriar ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Glutamate; GRM1a; iGLUR; mGLUR; Signaling

Indexed keywords

CALCIUM; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C;

AMINO ACID SEQUENCE; BIOLOGICAL MODEL; CALCIUM SIGNALING; CHEMISTRY; GENETICS; GRM1A; HUMAN; IGLUR; METABOLISM; MGLUR; MOLECULAR GENETICS; NEOPLASM; PHYSIOLOGY; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SIGNALING.;

GLUTAMATE; GRM1A; IGLUR; MGLUR; SIGNALING.;

AMINO ACID SEQUENCE; CALCIUM; CALCIUM SIGNALING; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUTAMIC ACID; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GLUTAMATE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; TYPE C PHOSPHOLIPASES;

EID: 84884572685     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6426     Document Type: Review

References (94)

1. Kelly A, Stanley CA. Disorders of glutamate metabolism. Mental retardation and developmental disabilities research reviews. 2001; 7: 287-95.
2. Alix JJ, Domingues AM. White matter synapses: form, function, and dysfunction. Neurology. 2011; 76: 397-404.
3. Fairman WA, Amara SG. Functional diversity of excitatory amino acid transporters: ion channel and transport modes. The American journal of physiology. 1999; 277: F481-6.
4. Ribeiro FM, Paquet M, Cregan SP, Ferguson SS. Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS & neurological disorders drug targets. 2010; 9: 574-95.
5. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 4240-6.
6. Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues. Pharmacological reviews. 2011; 63: 35-58.
7. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacological reviews. 2010; 62: 405-96.
8. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annual review of pharmacology and toxicology. 1997; 37: 205-37.
9. Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochimica et biophysica acta. 2012; 1822: 675-84.
10. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta pharmacologica Sinica. 2009; 30: 379-87.
11. Jaiswal MK, Zech WD, Goos M, Leutbecher C, Ferri A, Zippelius A, et al. Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC neuroscience. 2009; 10: 64.
12. Park E, Velumian AA, Fehlings MG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. Journal of neurotrauma. 2004; 21: 754-74.
13. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. European journal of pharmacology. 2013; 698: 6-18.
14. Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. Journal of cellular physiology. 2011; 226: 2484-93.
15. Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. The Biochemical journal. 2001; 359: 465-84.
16. Beqollari D, Kammermeier PJ. Venus fly trap domain of mGluR1 functions as a dominant negative against group I mGluR signaling. Journal of neurophysiology. 2010; 104: 439-48.
17. Muto T, Tsuchiya D, Morikawa K, Jingami H. Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 3759-64.
18. Seebahn A, Sticht H, Enz R. Expression, purification, and structural analysis of intracellular C-termini from metabotropic glutamate receptors. Methods in enzymology. 2013; 520: 257-79.
19. Shiraishi-Yamaguchi Y, Furuichi T. The Homer family proteins. Genome biology. 2007; 8: 206.
20. Brown E, Quinn S, Vassilev P. The Plasma Membrane Calcium Sensor. In: Carafoli E, Klee CB, editors. Calcium as a Cellular Regulator. Oxford, NY: Oxford University Press. 1993: 295-310.
21. Brauner-Osborne H, Wellendorph P, Jensen AA. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Current drug targets. 2007; 8: 169-84.
22. Magno AL, Ward BK, Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endocrine reviews. 2011; 32: 3-30.
23. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. Journal of cell science. 2003; 116: 4867-9.
24. Romano C, Yang WL, O'Malley KL. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. The Journal of biological chemistry. 1996; 271: 28612-6.
25. El Moustaine D, Granier S, Doumazane E, Scholler P, Rahmeh R, Bron P, et al. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109: 16342-7.
26. Iwazumi T. Myofibril tension fluctuations and molecular mechanisms of contraction. Advances in experimental medicine and biology. 1988; 226: 595-608.
27. Lampinen M, Pentikainen O, Johnson MS, Keinanen K. AMPA receptors and bacterial periplasmic amino acid-binding proteins share the ionic mechanism of ligand recognition. The EMBO journal. 1998; 17: 4704-11.
28. Kubo Y, Miyashita T, Murata Y. Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors. Science. 1998; 279: 1722-5.
29. Jiang Y, Huang Y, Wong HC, Zhou Y, Wang X, Yang J, et al. Elucidation of a novel extracellular calcium-binding site on metabotropic glutamate receptor 1{alpha} (mGluR1{alpha}) that controls receptor activation. The Journal of biological chemistry. 2010; 285: 33463-74.
30. Francesconi A, Duvoisin RM. Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. The Journal of biological chemistry. 1998; 273: 5615-24.
31. Pin JP, Joly C, Heinemann SF, Bockaert J. Domains involved in the specificity of G protein activation in phospholipase C-coupled metabotropic glutamate receptors. The EMBO journal. 1994; 13: 342-8.
32. Gomeza J, Joly C, Kuhn R, Knopfel T, Bockaert J, Pin JP. The second intracellular loop of metabotropic glutamate receptor 1 cooperates with the other intracellular domains to control coupling to G-proteins. The Journal of biological chemistry. 1996; 271: 2199-205.
33. Pin JP, Gomeza J, Joly C, Bockaert J. The metabotropic glutamate receptors: their second intracellular loop plays a critical role in the G-protein coupling specificity. Biochemical Society transactions. 1995; 23: 91-6.
34. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual review of pharmacology and toxicology. 2010; 50: 295-322.
35. Mateos JM, Benitez R, Elezgarai I, Azkue JJ, Lazaro E, Osorio A, et al. Immunolocalization of the mGluR1b splice variant of the metabotropic glutamate receptor 1 at parallel fiber-Purkinje cell synapses in the rat cerebellar cortex. Journal of neurochemistry. 2000; 74: 1301-9.
36. Berthele A, Laurie DJ, Platzer S, Zieglgansberger W, Tolle TR, Sommer B. Differential expression of rat and human type I metabotropic glutamate receptor splice variant messenger RNAs. Neuroscience. 1998; 85: 733-49.
37. Hiltscher R, Seuwen K, Boddeke HW, Sommer B, Laurie DJ. Functional coupling of human metabotropic glutamate receptor hmGlu1d: comparison to splice variants hmGlu1a and -1b. Neuropharmacology. 1998; 37: 827-37.
38. Houamed KM, Kuijper JL, Gilbert TL, Haldeman BA, O'Hara PJ, Mulvihill ER, et al. Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain. Science. 1991; 252: 1318-21.
39. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature. 1991; 349: 760-5.
40. Desai MA, Burnett JP, Mayne NG, Schoepp DD. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter. Molecular pharmacology. 1995; 48: 648-57.
41. Laurie DJ, Boddeke HW, Hiltscher R, Sommer B. HmGlu1d, a novel splice variant of the human type I metabotropic glutamate receptor. European journal of pharmacology. 1996; 296: R1-R3.
42. Huang X, Miller M. A time-efficient, linear-space local similarity algorithm. Adv Appl Math. 1991; 12: 337-57.
43. Hermans E, Challiss RA, Nahorski SR. Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists. British journal of pharmacology. 1999; 126: 873-82.
44. Hermans E, Young KW, Challiss RA, Nahorski SR. Effects of human type 1alpha metabotropic glutamate receptor expression level on phosphoinositide and Ca2+ signalling in an inducible cell expression system. Journal of neurochemistry. 1998; 70: 1772-5.
45. Esseltine JL, Willard MD, Wulur IH, Lajiness ME, Barber TD, Ferguson SS. Somatic mutations in GRM1 in cancer alter metabotropic glutamate receptor 1 intracellular localization and signaling. Molecular pharmacology. 2013; 83: 770-80.
46. Costantino G, Pellicciari R. Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists. Journal of medicinal chemistry. 1996; 39: 3998-4006.
47. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995; 34: 1-26.
48. Beneken J, Tu JC, Xiao B, Nuriya M, Yuan JP, Worley PF, et al. Structure of the Homer EVH1 domain-peptide complex reveals a new twist in polyproline recognition. Neuron. 2000; 26: 143-54.
49. Luo P, Li X, Fei Z, Poon W. Scaffold protein Homer 1: implications for neurological diseases. Neurochemistry international. 2012; 61: 731-8.
50. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron. 1998; 21: 717-26.
51. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron. 1998; 21: 707-16.
52. Fagni L, Chavis P, Ango F, Bockaert J. Complex interactions between mGluRs, intracellular Ca2+ stores and ion channels in neurons. Trends in neurosciences. 2000; 23: 80-8.
53. Wang JQ, Fibuch EE, Mao L. Regulation of mitogen-activated protein kinases by glutamate receptors. Journal of neurochemistry. 2007; 100: 1-11.
54. Anwyl R. Metabotropic glutamate receptor-dependent long-term potentiation. Neuropharmacology. 2009; 56: 735-40.
55. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of clinical investigation. 2008; 118: 3051-64.
56. Heuss C, Scanziani M, Gahwiler BH, Gerber U. G-protein-independent signaling mediated by metabotropic glutamate receptors. Nature neuroscience. 1999; 2: 1070-7.
57. Kim CH, Braud S, Isaac JT, Roche KW. Protein kinase C phosphorylation of the metabotropic glutamate receptor mGluR5 on Serine 839 regulates Ca2+ oscillations. The Journal of biological chemistry. 2005; 280: 25409-15.
58. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron. 1999; 23: 583-92.
59. Ramakers GM, Pasinelli P, Hens JJ, Gispen WH, De Graan PN. Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates. Progress in neuro-psychopharmacology & biological psychiatry. 1997; 21: 455-86.
60. Dhami GK, Ferguson SS. Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacology & therapeutics. 2006; 111: 260-71.
61. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, Kapp JA, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nature neuroscience. 2003; 6: 1153-61.
62. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nature reviews Molecular cell biology. 2012; 13: 283-96.
63. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends in biochemical sciences. 2009; 34: 620-7.
64. Liu L, Parent CA. Review series: TOR kinase complexes and cell migration. The Journal of cell biology. 2011; 194: 815-24.
65. Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chinese journal of cancer. 2012; 31: 8-18.
66. Chong ZZ, Kang JQ, Maiese K. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histology and histopathology. 2003; 18: 173-89.
67. Allen JW, Knoblach SM, Faden AI. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell death and differentiation. 2000; 7: 470-6.
68. Pshenichkin S, Dolinska M, Klauzinska M, Luchenko V, Grajkowska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation - possible role as a dependence receptor. Neuropharmacology. 2008; 55: 500-8.
69. Maiese K, Chong ZZ, Shang YC, Hou J. Therapeutic promise and principles: metabotropic glutamate receptors. Oxidative medicine and cellular longevity. 2008; 1: 1-14.
70. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug discovery today. 2011; 16: 485-94.
71. Schelman WR, Andres RD, Sipe KJ, Kang E, Weyhenmeyer JA. Glutamate mediates cell death and increases the Bax to Bcl-2 ratio in a differentiated neuronal cell line. Brain research Molecular brain research. 2004; 128: 160-9.
72. Mantovani A. Molecular pathways linking inflammation and cancer. Current molecular medicine. 2010; 10: 369-73.
73. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Annals of medicine. 2010; 42: 161-70.
74. Alsina FC, Ledda F, Paratcha G. New insights into the control of neurotrophic growth factor receptor signaling: implications for nervous system development and repair. Journal of neurochemistry. 2012; 123: 652-61.
75. Faissner A, Heck N, Dobbertin A, Garwood J. DSD-1-Proteoglycan/Phosphacan and receptor protein tyrosine phosphatase- beta isoforms during development and regeneration of neural tissues. Advances in experimental medicine and biology. 2006; 557: 25-53.
76. Boersma MC, Dresselhaus EC, De Biase LM, Mihalas AB, Bergles DE, Meffert MK. A requirement for nuclear factor-kappaB in developmental and plasticity- associated synaptogenesis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011; 31: 5414-25.
77. Gutierrez H, Hale VA, Dolcet X, Davies A. NF-kappaB signalling regulates the growth of neural processes in the developing PNS and CNS. Development. 2005; 132: 1713-26.
78. Tabata T, Kano M. Calcium dependence of native metabotropic glutamate receptor signaling in central neurons. Molecular neurobiology. 2004; 29: 261-70.
79. Stevens FC. Calmodulin: an introduction. Canadian journal of biochemistry and cell biology = Revue canadienne de biochimie et biologie cellulaire. 1983; 61: 906-10.
80. Rebola N, Lujan R, Cunha RA, Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron. 2008; 57: 121-34.
81. Pelkey KA, Topolnik L, Lacaille JC, McBain CJ. Compartmentalized Ca(2+) channel regulation at divergent mossy-fiber release sites underlies target cell-dependent plasticity. Neuron. 2006; 52: 497-510.
82. Topolnik L, Azzi M, Morin F, Kougioumoutzakis A, Lacaille JC. mGluR1/5 subtype-specific calcium signalling and induction of long-term potentiation in rat hippocampal oriens/alveus interneurones. The Journal of physiology. 2006; 575: 115-31.
83. Hermans E, Saunders R, Selkirk JV, Mistry R, Nahorski SR, Challiss RA. Complex involvement of pertussis toxin-sensitive G proteins in the regulation of type 1alpha metabotropic glutamate receptor signaling in baby hamster kidney cells. Molecular pharmacology. 2000; 58: 352-60.
84. Selkirk JV, Price GW, Nahorski SR, Challiss RA. Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations. Neuropharmacology. 2001; 40: 645-56.
85. Aramori I, Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron. 1992; 8: 757-65.
86. Thomsen C. Metabotropic glutamate receptor subtype 1A activates adenylate cyclase when expressed in baby hamster kidney cells. Progress in neuro- psychopharmacology & biological psychiatry. 1996; 20: 709-26.
87. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nature medicine. 2001; 7: 1010-5.
88. Teh JL, Chen S. Glutamatergic signaling in cellular transformation. Pigment cell & melanoma research. 2012; 25: 331-42.
89. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 5888-901.
90. Willard SS, Koochekpour s. Glutamate signaling in benign and malignant disorders: Current status, future perspectives, and therapeutic implications. Int J Biol Sci 2013; 9(7):728-742. doi:10.7150/ijbs.6475.
91. Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology. 2011; 76: 1344-52.
92. Sokol DK, Chen D, Farlow MR, Dunn DW, Maloney B, Zimmer JA, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. Journal of child neurology. 2006; 21: 444-9.
93. Bailey AR, Giunta BN, Obregon D, Nikolic WV, Tian J, Sanberg CD, et al. Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. International journal of clinical and experimental medicine. 2008; 1: 338-44.
94. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends in neurosciences. 2004; 27: 370-7.